Axiom-4 Mission to Study Insulin in Space, Paving Way for Diabetes Breakthroughs

The Axiom-4 mission to the International Space Station (ISS), featuring Indian astronaut Shubhanshu Shukla, is set to unlock new frontiers in medical science, particularly for diabetes care. In a first-of-its-kind experiment, the mission will explore how glucose and insulin behave in microgravity, offering fresh insights into treatment possibilities for diabetic patients on Earth and in space.

The experiment, dubbed “Suite Ride,” is a collaborative effort between UAE-based healthcare provider Burjeel Holdings and Axiom Space. During their 14-day stay on the ISS, some of the Axiom-4 astronauts will wear continuous glucose monitors (CGMs) to track changes in their glucose levels in a zero-gravity environment.

The research aims to aid in the development of wearable technologies that can benefit not only astronauts but also individuals with limited mobility, such as bedridden patients or those with paralysis.

“This could revolutionise diabetes management by helping us better understand insulin dynamics in unique physiological conditions,” experts associated with the mission said.

If successful, the findings from the Axiom-4 mission could mark a significant leap toward ensuring space travel is accessible even for people living with chronic conditions like diabetes.